ProQR Therapeutics (PRQR) Other financing activities (2014 - 2025)

ProQR Therapeutics has reported Other financing activities for 13 years, with the latest figure at $70476.3 in Q1 2025.

• Quarterly Other financing activities fell 59.95% year-over-year to $70476.3 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $260487.7 (down 24.44% YoY) and the FY2021 annual result came in at $1.8 million, up 114.06% from the prior year.
• Other financing activities grew to $70476.3 in Q1 2025 per PRQR's latest filing, from $1098.2 in the prior quarter.
• Over five years, Other financing activities peaked at $686348.3 in Q1 2021 and troughed at $1098.2 in Q3 2024.
• A 5-year average of $205884.7 and a median of $164377.2 in 2023 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2021 and 2024: Other financing activities jumped 132464.32% in 2021, then plunged 99.33% in 2024.
• Over 5 years, Other financing activities stood at $415261.5 in 2021, then plunged by 91.08% to $37037.1 in 2022, then soared by 343.82% to $164377.2 in 2023, then sank by 99.33% to $1098.2 in 2024, then soared by 6317.32% to $70476.3 in 2025.
• According to Business Quant data, Other financing activities over the past three periods registered $70476.3, $1098.2, and $12922.7 for Q1 2025, Q3 2024, and Q2 2024 respectively.